FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040377946> ?p ?o ?g. }

• W2040377946 endingPage "4117" @default.
• W2040377946 startingPage "4110" @default.
• W2040377946 abstract "BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 months of platinum-containing chemotherapy. METHODS: Patients with UC were eligible if they received a prior platinum-based regimen in the neoadjuvant/adjuvant setting or as first-line treatment for advanced/metastatic disease and had developed disease progression within 12 months. Vinflunine was administered intravenously every 3 weeks. Patients with Karnofsky performance status of 80 or 90, impaired renal function, prior pelvic irradiation, or age ≥75 years received an initial dose of 280 mg/m2, which was escalated to 320 mg/m2 in Cycle 2 if well tolerated. All other patients received an initial dose of 320 mg/m2. The primary endpoint was response rate defined by an independent response review committee (IRRC). RESULTS: Per the IRRC, 22 patients achieved a partial response, with a response rate of 15% (95% confidence interval, 9%-21%) with a median duration of response of 6.0 months. Sixty-four (42%) patients had stable disease. The median progression-free survival was 2.8 months, and the median overall survival was 8.2 months. Myelosuppression was the most frequent adverse event, with grade 3 of 4 (adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria [version 2.0] guidelines) neutropenia reported in 58% of the patients. Grade 3 of 4 febrile neutropenia occurred in 10 (7%) patients. Nonhematologic treatment-related events (grade 3 of 4) were generally manageable and included constipation (17%), asthenia/fatigue (13%), ileus (5%), and abdominal pain (5%). No cumulative toxicity was observed. CONCLUSIONS: Vinflunine demonstrates moderate activity in patients with platinum-pretreated UC. Toxicity is manageable and noncumulative. Cancer 2009. © 2009 American Cancer Society." @default.
• W2040377946 created "2016-06-24" @default.
• W2040377946 creator A5003107448 @default.
• W2040377946 creator A5004935250 @default.
• W2040377946 creator A5004985848 @default.
• W2040377946 creator A5007393455 @default.
• W2040377946 creator A5027947135 @default.
• W2040377946 creator A5035439869 @default.
• W2040377946 creator A5036164870 @default.
• W2040377946 creator A5050042851 @default.
• W2040377946 creator A5083967360 @default.
• W2040377946 creator A5087836779 @default.
• W2040377946 creator A5088131964 @default.
• W2040377946 date "2009-09-15" @default.
• W2040377946 modified "2023-10-14" @default.
• W2040377946 title "Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma" @default.
• W2040377946 cites W1893740135 @default.
• W2040377946 cites W1985014438 @default.
• W2040377946 cites W1993976101 @default.
• W2040377946 cites W2013206317 @default.
• W2040377946 cites W2037174072 @default.
• W2040377946 cites W2041435757 @default.
• W2040377946 cites W2061938790 @default.
• W2040377946 cites W2064885466 @default.
• W2040377946 cites W2065110636 @default.
• W2040377946 cites W2066984265 @default.
• W2040377946 cites W2101562875 @default.
• W2040377946 cites W2103257412 @default.
• W2040377946 cites W2135889186 @default.
• W2040377946 cites W2246945802 @default.
• W2040377946 doi "https://doi.org/10.1002/cncr.24460" @default.
• W2040377946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19536904" @default.
• W2040377946 hasPublicationYear "2009" @default.
• W2040377946 type Work @default.
• W2040377946 sameAs 2040377946 @default.
• W2040377946 citedByCount "108" @default.
• W2040377946 countsByYear W20403779462012 @default.
• W2040377946 countsByYear W20403779462013 @default.
• W2040377946 countsByYear W20403779462014 @default.
• W2040377946 countsByYear W20403779462015 @default.
• W2040377946 countsByYear W20403779462016 @default.
• W2040377946 countsByYear W20403779462017 @default.
• W2040377946 countsByYear W20403779462018 @default.
• W2040377946 countsByYear W20403779462019 @default.
• W2040377946 countsByYear W20403779462020 @default.
• W2040377946 countsByYear W20403779462021 @default.
• W2040377946 countsByYear W20403779462023 @default.
• W2040377946 crossrefType "journal-article" @default.
• W2040377946 hasAuthorship W2040377946A5003107448 @default.
• W2040377946 hasAuthorship W2040377946A5004935250 @default.
• W2040377946 hasAuthorship W2040377946A5004985848 @default.
• W2040377946 hasAuthorship W2040377946A5007393455 @default.
• W2040377946 hasAuthorship W2040377946A5027947135 @default.
• W2040377946 hasAuthorship W2040377946A5035439869 @default.
• W2040377946 hasAuthorship W2040377946A5036164870 @default.
• W2040377946 hasAuthorship W2040377946A5050042851 @default.
• W2040377946 hasAuthorship W2040377946A5083967360 @default.
• W2040377946 hasAuthorship W2040377946A5087836779 @default.
• W2040377946 hasAuthorship W2040377946A5088131964 @default.
• W2040377946 hasBestOaLocation W20403779462 @default.
• W2040377946 hasConcept C121608353 @default.
• W2040377946 hasConcept C126322002 @default.
• W2040377946 hasConcept C141071460 @default.
• W2040377946 hasConcept C143998085 @default.
• W2040377946 hasConcept C197934379 @default.
• W2040377946 hasConcept C203092338 @default.
• W2040377946 hasConcept C2776694085 @default.
• W2040377946 hasConcept C2777063308 @default.
• W2040377946 hasConcept C2778822529 @default.
• W2040377946 hasConcept C2778850193 @default.
• W2040377946 hasConcept C2780352672 @default.
• W2040377946 hasConcept C2781413609 @default.
• W2040377946 hasConcept C2911057145 @default.
• W2040377946 hasConcept C3019882237 @default.
• W2040377946 hasConcept C535046627 @default.
• W2040377946 hasConcept C71924100 @default.
• W2040377946 hasConceptScore W2040377946C121608353 @default.
• W2040377946 hasConceptScore W2040377946C126322002 @default.
• W2040377946 hasConceptScore W2040377946C141071460 @default.
• W2040377946 hasConceptScore W2040377946C143998085 @default.
• W2040377946 hasConceptScore W2040377946C197934379 @default.
• W2040377946 hasConceptScore W2040377946C203092338 @default.
• W2040377946 hasConceptScore W2040377946C2776694085 @default.
• W2040377946 hasConceptScore W2040377946C2777063308 @default.
• W2040377946 hasConceptScore W2040377946C2778822529 @default.
• W2040377946 hasConceptScore W2040377946C2778850193 @default.
• W2040377946 hasConceptScore W2040377946C2780352672 @default.
• W2040377946 hasConceptScore W2040377946C2781413609 @default.
• W2040377946 hasConceptScore W2040377946C2911057145 @default.
• W2040377946 hasConceptScore W2040377946C3019882237 @default.
• W2040377946 hasConceptScore W2040377946C535046627 @default.
• W2040377946 hasConceptScore W2040377946C71924100 @default.
• W2040377946 hasIssue "18" @default.
• W2040377946 hasLocation W20403779461 @default.
• W2040377946 hasLocation W20403779462 @default.
• W2040377946 hasLocation W20403779463 @default.
• W2040377946 hasOpenAccess W2040377946 @default.
• W2040377946 hasPrimaryLocation W20403779461 @default.

• next